ClinicalTrials.gg
Status unknownNCT05068141Updated Oct 15, 2021

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

A Phase 2 interventional study of SG001 and Nab-paclitaxel in Triple Negative Breast Cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-10-15.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
128th of 235
79 · median 90
Started
2021
with 17 others
Phase 2
124 of 252
65 open now
Registered
97th of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 128th largest by planned enrollment of the 235 interventional ones that give a count, is one of 18 that started in 2021, is one of 124 in phase 2, and was the 97th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of SG001 in combination with Nab-paclitaxel in patients with advanced TNBC.

Read the detailed description

This study is a single-arm, open label, multicenter phase II study to evaluate the efficacy and safety of SG001 in combination with nab-paclitaxel in patients with unresectable locally advanced, or recurrent, or metastatic TNBC. Eligible patients will receive SG001 intravenous infusion at a dose of 240 mg on Days 1 and 15 of every 4-week cycle and nab-paclitaxel intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or intolerable toxicity, or other discontinuation or termination criteria are met, for a maximum of 2 years.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • Triple negative breast cancer (TNBC)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients, aged 18-70 years (inclusive), voluntarily join the study and sign the form.
  2. (ECOG) (ECOG): 0 \~ 1 point;
  3. confirmed TNBC, namely, human epidermal growth receptor 2-negative (-negative) and estrogen receptor-negative (ER-negative) and progesterone receptor-negative (PR-negative); Patients with confirmed TNBC lesions are eligible.
  4. Patients with locally advanced (staging according to AJCC 8th Edition) inoperable or recurrent/metastatic TNBC who have received ≤ 1-line system treatment. The number of treatment-naïve patients and the pre-treated patients should be approximately in equal numbers. The interval ≥ 6 months between the end of taxane-based /neoadjuvant therapy and the occurrence of recurrence/metastasis, and an interval ≥ 3 months between the end of taxane-based therapy for advanced breast cancer and the occurrence of recurrence/metastasis.
  5. Provide archived tissue for detecting the expression level of , or if not available, agree to perform a tumor tissue for PD-L1 detection during the screening period.

    1. The proportion of patients with CPS ≥ 10 should be ≥ 20% and ≤ 50% of all patients;
    2. The archived tissue must be representative of the latest tumor specimen, and the relevant pathological reports of the above specimens must also be provided;
    3. Fresh tissue specimens can be obtained by surgical resection and biopsy; Fine needle aspiration and liquid based cytology (TCT) samples are not accepted (i.e. samples lacking complete tissue structure and providing only cell suspension and/or cell smear);
    4. For patients with negative PD-L1 in the initially archived tumor tissue samples, biopsy can be performed during screening period to redetect the expression status of PD-L1 with the consent of the patients, and a positive tumor tissue sample of any kind is considered PD-L1 positive (i.e. CPS ≥ 1);
  6. At least one confirmed by CT or MRI at baseline as per the solid tumor efficacy evaluation criteria ( v1.1). The measurable lesions should not have received local treatment such as radiotherapy (lesions located in the previous radiotherapy area can also be selected as target lesions if progression is confirmed);
  7. Estimated survival time ≥ 12 weeks;
  8. Adequate organ function, defined by the following laboratory results obtained within 14 days prior to the enrollment::

    1. Blood routine (no blood transfusion within 14 days before the first administration, no hematopoietic stimulating factor and no other drugs to correct the number of blood cells): (ANC) ≥ 1.5 × 109/L; count (PLT) ≥ 75 × 109/L; (HGB) ≥ 9 g/dL;
    2. Blood biochemistry: serum creatinine (Cr) ≤ 1.5 × or (CCR) ≥ 50 mL/min; Total (TBIL) ≤ 1.5 × ULN (≤ 3 × ULN for patients with Gilbert's syndrome); (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN for patients with hepatocellular carcinoma or liver metastasis);
    3. Coagulation function: (APTT) and international standardized ratio (INR) ≤ 1.5 × ULN (not corrected with anticoagulants or other drugs affecting coagulation function within 14 days before the first dose, except for the long-term use of anticoagulants due to the patient's disease);
  9. Women of childbearing age must take adequate measures from the signing of informed consent to 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Known to recombinant all human monoclonal antibody drugs and its components, or known allergy to any paclitaxel or albumin bound paclitaxel component; A history of uncontrollable allergic asthma;
  2. Previously diagnosed other within 3 years prior to screening, except for adequately treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, thyroid cancer or cured in situ carcinoma, such as cervical carcinoma in situ;
  3. Patients with active disease or history of autoimmune disease, except for well-controlled type I diabetes, well-controlled hypothyroidism only requiring hormone replacement therapy, skin disease that do not require systemic treatment (such as vitiligo, psoriasis, or alopecia), or patients whose diseases are not expected to recur in the absence of external triggers;
  4. Patients with a history of primary immunodeficiency;
  5. Patients with serious cardiovascular diseases, such as heart failure rated as grade 2 or above by the (NYHA) classification, myocardial infarction within 3 months before screening, poorly controlled arrhythmia or unstable angina pectoris, or serious arterial/venous thrombotic events (such as , cerebral hemorrhage, cerebral infarction, deep vein thrombosis and pulmonary embolism, etc.) within 3 months prior to screening;
  6. Interstitial lung disease requiring systemic therapy of ;
  7. Known untreated central nervous system (CNS) and meningeal metastasis, or treated but still symptomatic and meningeal metastasis; However, asymptomatic untreated CNS metastasis and meningeal metastasis, and treated and symptomatically stable CNS metastasis and meningeal metastasis can be included.
  8. Have received any other antibodies/drugs that act on T-cell co-stimulation or checkpoint pathway (including but not limited to PD-1, PD-L1, PD-L2, CTLA-4, OX40, c137 inhibitors, etc.);
  9. Major surgery within 28 days before the first dose of study treatment, radiotherapy within 14 days before the first dose of study treatment, or use of radiation agents (strontium, or samarium, etc.) within 56 days before the first administration;
  10. Systemic antitumor therapy within 14 days before the first administration;
  11. Patients who have received within 28 days before the first administration or planned to receive it during the study period.
  12. Any Chinese patent medicine treatment with an approved antitumor indication by NMPA or Chinese herbal medicine treatment for the purpose of antitumor which is clearly recorded in the medical record within 14 days before the first administration;
  13. Active tuberculosis;
  14. Active infection requiring intravenous infusion treatment within 14 days before the first administration;
  15. Received glucocorticoid (prednisone > 10 mg/day or equivalent dose of other similar drugs) or other treatment for some conditions within 14 days before the first administration;
  16. Those who have received other test drugs within 28 days before the first administration;
  17. antibody (HIV-Ab) or treponema pallidum antibody (TP-AB) positive; virus surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive, with hepatitis B virus quantitative detection value > (ULN) value of the detected center; antibody (HCV-Ab) positive, with hepatitis B virus RNA quantification > ULN value of the detected center.
  18. Pregnant or lactating women; Or positive test for blood pregnancy during screening;
  19. Other situations that may increase the risks related to the study medication, interfere with the interpretation of the study results, affect compliance of the trial, etc. are determined by the investigator to be not suitable for the trial.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (estimated)

Study arms

  • Experimental
    SG001 plus Nab-Paclitaxel

    Patients will receive SG001 intravenously at a dose of 240 mg on Days 1 and 15 of every 4-week cycle in combination with nab-paclitaxel at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or unacceptable toxicity, or other discontinuation or termination criteria are met.

    Drug: SG001 · Drug: Nab-paclitaxel

Interventions

  • DrugSG001

    Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w

  • Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR will be assessed by RECIST 1.1 criteria.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: Up to approximately 2 years

  2. Duration of response (DOR)

    Time frame: Up to approximately 2 years

  3. Disease control rate (DCR)

    Time frame: Up to approximately 2 years

  4. Overall survival (OS)

    Time frame: Up to approximately 2 years

  5. Progression free survival (PFS) in patients with combined positive score (CPS) ≥ 10

    Time frame: Up to approximately 2 years

  6. Objective response rate (ORR) in patients with CPS ≥ 10

    Time frame: Up to approximately 2 years

  7. Duration of response (DOR) in patients with CPS ≥ 10

    Time frame: Up to approximately 2 years

  8. Disease control rate (DCR) in patients with CPS ≥ 10

    Time frame: Up to approximately 2 years

  9. Overall survival (OS) in patients with CPS ≥ 10

    Time frame: Up to approximately 2 years

  10. Treatment emergent adverse event (TEAEs)

    Time frame: Throughout the study period, with an average of 2 years

  11. Maximum Serum Concentration (Cmax) for SG001 Maximum Serum Concentration for SG001 Maximum Serum Concentration (Cmax) for SG001

    Maximum Serum Concentration for SG001

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  12. Minimum Serum Concentration (Cmin) for SG001

    Minimum Serum Concentration for SG001

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  13. Plasma Concentrations of Total and Free Paclitaxel

    Plasma Concentrations of Total and Free Paclitaxel

    Time frame: Pre-dose on Cycle 1 Day 1. End of nab-paclitaxel infusion, 4 hours after end of nab-paclitaxel infusion on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  14. Immunogenicity

    Anti-drug antibodies (ADA) and neutralizing antibodies

    Time frame: Up to approximately 2 years

Other outcomes

  1. Correlation between clinical characteristics and efficacy

    Clinical characteristics includes intestinal flora, gene mutations, PD-L1 expression, biomarkers, etc.

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Oct 2022, 12 months after the start.

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Oct 5, 2021
StartActual
Oct 1, 2021
Primary completionEst.
Oct 1, 2022
CompletionEst.
Oct 1, 2023
Last update
Oct 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05068141
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Oct 1, 2021
Primary completion
Oct 1, 2022 (estimated)
Completion
Oct 1, 2023 (estimated)
Last update
Oct 15, 2021

Study contacts

beibei Zhai
Contact
zhaibeibei@mail.ecspc.com
+86-021-60673937
herui yao
study chair · Sun Yat-sen Memorial Hospital,Sun Yat-sen University
wang ying
study chair · Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlonstobart

Start the discussion